Stock 600867 TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Tonghua Dongbao Pharmaceutical Co., Ltd.

Equities

600867

CNE000000H87

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 22/05/2024 BST 		5-day change 1st Jan Change
9.58 CNY -4.20% Intraday chart for Tonghua Dongbao Pharmaceutical Co., Ltd. -4.49% -11.54%
05-15 Tonghua Dongbao Pharmaceutical Launches Phase 1 Trial for Diabetes Injection in China MT
05-10 Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake
MT
Dongbao Pharmaceutical's Profit, Operating Income Slip in Q1 2024
MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Dongbao Pharma's 2023 Profit Drops 26%
MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Dongbao Pharma Unit's Gout Drug Clinical Study Achieves Primary Endpoint
MT
Dongbao Pharmaceutical's Unit Gets Nod to Trial Diabetes Drug
MT
Dongbao Pharmaceutical Unit Gets Nod to Trial Diabetes Drug
MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Adocia Announces its Partner Tonghua Dongbao Releases Positive Results on the Three Clinical Studies Conducted on BioChaperone Combo THDB0207 Formulation Containing Insulin Glargine and Insulin Lispro from Tonghua Dongbao
CI
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Announces an Exclusive Licensing Agreement with Tonghua Dongbao Pharmaceutical Co., Ltd. to Commercialize Three Insulin Biosimilars - Insulin Aspart, Insulin Lispro, and Insulin Glargine in the U.S
CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Tonghua Dongbao Pharma’s Net Profit Jumps 21% Despite Revenue Drop
MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Tonghua Dongbao Gets Regulatory Approval For Two Insulin Injections
MT
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022.
CI
Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback announced on June 15, 2022, has expired with 15,699,918 shares, representing 0.78% for CNY 143.57 million.
CI
Tonghua Dongbao Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 600867 Stock
  4. News Tonghua Dongbao Pharmaceutical Co., Ltd.
  5. Highlights